Recommended Readings: Michel C. Nussenzweig, M.D., Ph.D.

Friday Lecture Series

Ph.D. Recruitment Lecture

The HIV Vaccine Problem

Michel C. Nussenzweig, M.D., Ph.D., Sherman Fairchild Professor,

senior physician, The Rockefeller University;

investigator, Howard Hughes Medical Institute

 March 8, 2012

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

 

Recommended Readings

Mouquet, H., Warncke, M., Scheid, J. F., Seaman, M. S., & Nussenzweig, M. C. (2012). Enhanced HIV-1 neutralization by antibody heteroligation. Proceedings of the National Academy of Sciences of the United States of America, 109(3), 875-880

Nchinda, G., Kuroiwa, J., Oks, M., Trumpfheller, C., Chae, G. P., Huang, Y., . . . Steinman, R. M. (2008). The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. Journal of Clinical Investigation, 118(4), 1427-1436

Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., . . . Nussenzweig, M. C. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 333(6049), 1633-1637

Trumpfheller, C., Finke, J. S., López, C. B., Moran, T. M., Moltedo, B., Soares, H., . . . Steinman, R. M. (2006). Intensified and protective CD4 + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. Journal of Experimental Medicine, 203(3), 607-617

Zhou, T., Georgiev, I., Wu, X., Yang, Z. -., Dai, K., Finzi, A., . . . Kwong, P. D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329(5993), 811-817

Share

Recommended Readings: Bruce Walker, M.D.

Friday Lecture Series

Immune Control and Immune Failure in HIV Infection

Bruce Walker, M.D., Principal Investigator,

Ragon Institute of MGH, MIT and Harvard

April 13, 2012

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

 

Recommended Readings:

Huang, J., P. S. Burke, T. D. H. Cung, F. Pereyra, I. Toth, B. D. Walker, L. Borges, M. Lichterfeld, and X. G. Yu. 2010. “Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers.” Journal of Virology 84 (18): 9463-9471

Kawashima, Y., K. Pfafferott, J. Frater, P. Matthews, R. Payne, M. Addo, H. Gatanaga, et al. 2009. “Adaptation of HIV-1 to Human Leukocyte Antigen Class I.” Nature 458 (7238): 641-645

Mahalanabis, M., P. Jayaraman, T. Miura, F. Pereyra, E. M. Chester, B. Richardson, B. Walker, and N. L. Haigwood. 2009. “Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers.” Journal of Virology 83 (2): 662-672

Matthews, P. C., A. Prendergast, A. Leslie, H. Crawford, R. Payne, C. Rousseau, M. Rolland, et al. 2008. “Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point.” Journal of Virology 82 (17): 8548-8559

Pereyra, F., S. Palmer, T. Miura, B. L. Block, A. Wiegand, A. C. Rothchild, B. Baker, et al. 2009. “Persistent Low-Level Viremia in HIV-1 Elite Controllers and Relationship to Immunologic Parameters.” Journal of Infectious Diseases 200 (6): 984-990

Virgin, H. W. and B. D. Walker. 2010. “Immunology and the Elusive AIDS Vaccine.” Nature 464 (7286): 224-231

Share

Salk Institute Leads $21M HIV Research Focusing on Early Immune System Responses

NEW YORK (GenomeWeb News) – A new research consortium led by the Salk Institute of Biological Studies and the Sanford-Burnham Medical Research Institute will use a $21 million grant from the National Institutes of Health to conduct systems biology-based studies of the earliest immune system responses to HIV infection.

The multidisciplinary research effort will include DNA sequencing, expression analysis, RNAi analysis, mass spectrometry, and other efforts aimed at discovering the cellular protein mechanisms that are the first line of defense against HIV.

Along with Salk and Sanford-Burnham, the research program will fund research at the University of California, San Francisco; Mount Sinai School of Medicine; the University of California, San Diego; Northwestern University; and the University of Pennsylvania.

“The events that occur immediately after exposure to HIV, which determines the ability of the virus to establish infection and ultimately shape the course of the disease, are very poorly understood,” Sumit Chanda, an adjunct professor at the Salk Institute, said in statement.

“This grant funds a multi-center consortium that will integrate cutting edge technologies in systems biology and next-generation sequencing, with world-leading expertise in immunology and virology to decode and model the early molecular events that occur after HIV enters the body,” Chanda added. “These projects will be fundamental towards the development of safe and effective HIV vaccines, as well as novel preventative therapies for HIV.”

The research will include next-generation sequencing focused on identifying relevant polymorphisms at Northwestern University, microarray expression analysis at Burnham and Mount Sinai, high-throughput affinity purification mass-spec approaches at UCSF, and large-scale RNAi analysis projects at Sanford-Burnham, Chanda told GenomeWeb Daily News in an e-mail.

Share

ScienceDirect Publishes Quarterly Top 25 “Most Downloaded” Reports

ScienceDirect (Elsevier) publishes quarterly lists of the most highly downloaded papers.  ScienceDirect, Elsevier’s full text platform, offers access to over 2000 peer reviewed science/technology/medical journals.   You may subscribe to custom lists of “hottest” articles by choosing subject categories or individual journal titles.    Sign up to receive email notices at “TOP25.” Congratulations to Paul Bieniasz and other members of the Aaron Diamond research team on being among the latest “TOP25″ in Biochemistry, Genetics and Molecular Biology for their article in CELL on the activity of tetherin in HIV-1 infection.

Share

HIV-1 Rapid Immune System Damage In Early Stages of Infection

ScienceDaily (July 14, 2009) — The virus that causes AIDS is classified as a lentivirus, a word derived from the Latin prefix, “lenti-,” meaning “slow.” But new research from the NIAID-funded Center for HIV/AIDS Vaccine Immunology suggests that HIV-1 is anything but – moving at breathtaking speed in destroying and dysregulating the body’s gut-based B-cell antibody-producing system.    Read about the research conducted at Duke University.

Share

Lemur Genome May Provide HIV Insights

ScienceDaily (Dec. 2, 2008) — The genome of a lemur from Madagascar may provide new understanding how HIV-like viruses coevolved with primates.  The discovery published online in the Proceedings of the National Academy of Sciences, could provide insight into why non-human primates don’t get AIDS and lead to treatments for humans.  Rob Gifford, PhD, researcher in infectious diseases and geographical medicine is lead author of the new study.   Gifford searched primate species DNA for strings of nucleotides that matched the modern lentivirus genome and found one lurking in the DNA of the tiny gray mouse lemur.  Gifford’s work on lentivirus-primate interaction might open doors for HIV/AIDS research.

Share

Enhanced expression of T-cell receptors in CD8 T cells increases HIV-1 binding 450-fold

Investigators at the University of Pennsylvania School of Medicine and Cardiff University, UK have engineered T-cells which are able to recognize HIV-1 strains that typically fall under the radar.  In the November 9, 2008 advanced online Nature Medicine publication of Control of HIV-1 immune espcape by CD8 T cells expressing enhanced T-cell receptor, researchers describe T cells that bonded more strongly and in a more aggressive manner so that fewer T cells were required to control HIV-1 infection.

It is hoped that clinical trials with the engineered T-cells will begin in 2009 to establish safety.  If laboratory results can be translated effectively in the clinic, a powerful “disguise detection” therapy may emerge which could treat early-stage HIV-1 infections. 

(Extracts from ScienceDaily, November 10, 2008 and Nature Medicine published online November 9, 2008; doi:10.1038/nm.1779)

Share

Antibody Fragment Powerful HIV Inhibitor

Previous research has shown that reducing antibodies to the smallest independently functional fragment effectively extends their utility as therapeutic agents.   Researchers at NCI identified the domain fragment, m36, as having the ability to very strongly inhibit multiple HIV strains.  It also provides new insights into how the virus invades the call and neutralizes the immune system.   This research was published online October 20, 2008.  Chen, W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proceedings of the National Academy of Sciences.

Share

AIDS pioneers and HPV cancer researcher win Nobel Prize for medicine or physiology

On Monday, October 6, 2008, two French scientists who discovered the AIDS virus and a German scientist who found the virus the causes cervical cancer were awarded the Nobel prize for medicine or physiology.  A brief podcast and video describe these awards.

Luc Montagnier, director of the World Foundation for AIDS Research and Prevention, and Francoise Barre-Sinoussi of the Institut Pasteur won half of the prize for discovering the AIDS virus which has killed millions of people. 

Harald zur Hausen of the University of Duesseldorf shared the other half of the prize for work that ran counter to the current dogma related to the cause of cervical cancer. 

The French scientists identified virus production in lymphocytes from early-stage, acquired immunodeficiency patients and from blood from patients with late stages of the disease.  This virus became known as human immunodeficiency virus (HIV).  These findings led to the current understanding of the biology of the disease and antiretroviral treatment.

Harald zur Hausen was awarded the other half of the Nobel prize for work which proved that oncogenic human papilloma virus (HPV) casued cervical cancer, the second most common cancer in women.  This discovery led to understanding the basis for HPV infection and HPV-induced cancers and the subsequent development of prophylactic vaccines against HPV. 

Montagnier, upon receiving the honor, said that a treatment for AIDS could be possible in the future with a therapeutic, rather than a preventive vaccine.  A therapeutic vaccine prevents disease from fluorishing once it has taken hold.

Share